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1. Introduction 
Biotechnology generates global sales in the order of well over 200 billion US$ in all 
markets and has thus become an important economic factor in manufacturing. The buzz 
word ‘biotechnology’ carries expectations that it can provide sustainable solutions for 
greenhouse gas reduction in manufacturing industries, trigger a ‘clean tech’ boom and 
create new jobs. It is no wonder that biotechnology has gained significant attention even 
in high level politics as it can give a ‘green’ touch to administrations. Many consumers are 
not even aware of the surprising array of products and services which biotechnology can 
or could provide today; these range from high-tech pharmaceutical applications to snow 
making. Table 1 lists some new or unusual applications of biotechnology products which 
include, for example, skin protection compounds from the oceans or biopolymers for drag 
reduction in transport pipelines.  
 
 Microbial secondary metabolites for the bio-control of invasive mussels in water pipes 
 Microbial products for rust removal and anticorrosion 
 Proteins for plant protection by induction of the plant’s natural defence systems 
 Glycoproteins radically affecting the palate and sensorial perception 
 Compounds from deep-sea microorganisms for skin protection 
 Nanoscaffolds (also functionalized) based on biomaterial for e.g. tissue replacement and repair  
 Biopolymers and biosurfactants for drag reduction in transport pipelines 
 Biopolymers and enzymes for plywood production 
 Channel proteins for H2O desalination and other purposes  
 Enzymes as toxic gas antidotes for military applications 
 Microbially derived innovative lubricants 
 Biologicial production of solar cells  
 
Table 1. A few examples of new and unusual applications of biotechnology and its products 
in different fields. 
These high expectations are merited due for 4 reasons:  
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1. The unmatched precision in the production and assembly of small and large molecules. 
This precision of the natural biosynthetic machinery cannot be reached using chemical 
approaches.  
2. The fantastic speed, at which these production systems can reproduce themselves. The 
reason for this is that bacteria have by far the largest surface-to-volume ratio in the 
living world, leading to maximal metabolic rates. A single bacterium, weighing about 
10-12 grams, grows so fast that its biomass would theoretically reach the mass of the 
earth in only a few days!  
3. The inherent safety of biological systems as metabolic heat makes run-away reactions 
impossible, when compared to organic chemistry. 
4. The biocatalyst and biomass are fully recyclable.  
Consequently, biotechnology will have an especially high impact in the production of 
complex chemicals used for pharmaceuticals, fine chemicals and specialities (Meyer, 2011). 
Other promising areas are biopolymers and protein-based novel biomaterials for consumer 
goods, car parts, medical devices or as support for the 2D and 3D cultivation of tissue and 
organ replacements.  
It is industrial or white biotechnology which is of growing academic and private interest, 
as it represents an equal or even bigger business potential than red biotechnology in the 
long term. But how can application fields and markets of biotechnology be classified? One 
way to describe the different markets of biotechnology is the colour code (red, white, 
green, blue and grey).  
2. The markets 
A useful way to classify the applications of biotechnology is the colour code of 
biotechnology shown in Table 2.  
Estimates and definitions may vary, but there is one common denominator in various 
assessments, namely that the proportion of products manufactured using biotechnology will 
increase significantly. While the development and the market introduction of new 
biopharmaceuticals such as monoclonal antibodies will continue at its present rate, it is 
especially industrial biotechnology which is expected to realise high growth rates.  
The different “biotechnologies” do overlap and especially the boundaries especially 
between red and white biotechnologies for pharmaceutical applications can be confusing. 
There is one important additional difference between the red biotechnology of therapeutic 
proteins and monoclonal antibodies and the white biotechnology pharmaceuticals which 
includes a large variety of products: red biotechnology is characterised more by its products 
whereas white biotechnology is defined more by its technology platform.  
2.1 The chemical market 
The sales of global chemical markets are expected to grow from 2292 billion Euros in 2007 to 
3235 billion Euros in 2015 and to 4012 billion Euros in 2020 (Perlitz, 2008). It is estimated that 
only about 3-4% of all chemical sales have been generated with some help from biotechnology 
(Nieuwenhuizen et al., 2009), but this figure is anticipated to grow faster than the average 
market rate. It is speculated that at least 20% of the global chemicals will be derived using 
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industrial biotechnology in 2020, which translates into almost 1000 billion Euros. This means 
that the sales generated by industrial biotechnology will increase by an order of magnitude as 
the recent estimates of the global sales of industrial biotechnology products vary between 50 
and 150 billon Euros, depending on whether biofuels are included or not. There is a consensus 
that biotechnology will play a much greater role in future manufacturing as it can deliver 
complex products using economically and ecologically sustainable processes.  
 
Table 2. Classification of the applications of biotechnology with respect to markets; for 
each class sales volumes, compound annual growth rate and number of companies 
globally active in the field are noted; there is of course an overlap between industrial and 
pharmaceuticals biotechnology, some sectors of industrial biotechnology are dependent 
on cheap and reliable sources from agro biotechnology (Clive, 2010). The market size of 
>11 billion US$ for agro biotechnology refers to “seed biotech”. The global value of 
marketed harvested goods resulting from these seeds would be much larger, by one or 
two orders of magnitude.  
The products potentially produced by biotechnology range from commodities (e.g. succinic 
acid), biopolymers (e.g. polyhydroxybutyric acid), flavour & fragrance products (e.g. 
vanillin), agroproducts (Bacillus thuringiensis) to small molecule pharmaceuticals and more.  
Unfortunately there are no shortcuts in biotechnology, and in order to meet the anticipated 
1000 billion Euros derived from white or industrial biotechnology and to keep red 
biotechnology humming we need to further develop appropriate tools while keeping in 
mind that it took 200 years to complete today’s chemical toolbox (Ghisalba et al., 2010).  
2.2 The feed, food and dietary supplement markets 
Biotechnology plays an important role in the kitchen through the food and beverage 
industry. Enzymes are used in large scale food production of glucose from starch 
(hydrolytic enzymes), high fructose syrup (isomerase), conversion of lactose to galactose 
and glucose (hydrolase), cheese production (proteases), meat processing (proteases) and 
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many more. Phytase (phosphohydrolase) is an example of an enzyme used in the feed 
industry. However, only about 25% to 30% of all industrial enzymes are used for food and 
feed purposes. It is also worthwhile to note that over 90% of industrial enzymes sales come 
from less than 30 enzymes, most of them hydrolytic enzymes. As these enzymes are used as 
an auxiliary material in the food manufacturing process, most of them can be produced 
using recombinant technology. Thus microbial expression systems play a crucial role for 
enzyme production.  
The market of functional foods more than doubled between 2001 and 2010 and is estimated 
at 5 billion € (Welck & Ohlig, 2011). Other important biotechnology products are amino 
acids, vitamins or PUFAs (polyunsaturated fatty acids).  
Flavours and fragrances are also biotechnology-relevant markets with a volume of over 22 
billion US$ (Leffingwell & Associates, 2011). More than 10% of the supply is derived from 
bioprocesses, with more than 100 commercial aroma chemicals derived via different 
biotechnological methods (Berger, 2009). In order to relieve the pressure on natural resources, 
companies are increasingly turning towards novel biotechnological sources and methods 
including genetic engineering approaches for the production of these raw materials.  
This is also true for a part of the pharma market described below. To supply the anticancer 
secondary metabolite taxol (paxclitaxel) from its original natural source (the bark of the 
Pacific yew tree Taxus brevifolia) would be impossible. Taxol is produced in minute amounts 
(0.4 g/kg of bark) and synthetic alternatives including biotechnological steps had to be 
developed for this blockbuster drug with sales of about 3.5 billion US$. It is difficult to 
estimate the global market value of botanical or plant derived drugs (BCC Research, 2009), 
but they seem to grow at a CAGR of 11% and alternative commercially viable expression 
and production systems will be needed for their production to replace the extraction from 
endangered or slow growing plants.  
2.3 The pharmaceutical market 
According to the IMS Health Forecasts, the global pharmaceutical market is expected to 
grow at an overall rate of 5-7% per annum, to reach $880 billion US$ in 2011 (Gatyas, 2011). 
Of this total pharmaceutical market, monoclonal antibodies alone represented 43 billion US$ 
and therapeutic proteins 66 billion US$ (2009 figures, Market Research News, 2011). The 
numbers for small molecule pharmaceuticals, which represent a very fragmented market, 
are even more difficult to estimate. Franssen et al. estimated the market segment in 2010 for 
pharmaceutical ingredients using industrial biotechnology at about 20 bn US$ (Franssen et 
al, 2010). This could be conservative, as the number of small molecule APIs (Active 
Pharmaceutical Ingredients) using biotechnology in their (chemical) synthesis is rapidly 
increasing. Blockbuster such as Merck’s Sitagliptin or Pfizer’s Atorvastatin now include 
biotechnological steps in their manufacturing. Atorvastatin (Lipitor®), a cholesterol-
lowering small molecule drug is the largest selling drug in history, which peaked at 12.7 
billion US$ annual sales. The chemical synthesis includes a biocatalysis step using a 
ketoreductase. The same is true for MERCK’s Sitagliptin, the small molecule compound 
used in the antidiabetes drug Januvia®, which includes a transaminase step in its chemical 
synthesis. Taking such products into consideration, the number will increase well above 30 
billion US$ in 2011. Many classical biotechnological products like antibiotics (market of 42 
billion US$ in 2009) or steroids are even not included in these 30 billion US$. What is 
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important is that the small molecule market remains by far the most important driver for 
innovation in industrial biotechnology (Meyer et al., 2009).  
It is especially red biotechnology with therapeutic proteins and monoclonal antibodies 
which is thriving and driving growth with established technologies. Remicade was the top 
selling mAbs brand followed by Avastin®, Rituxan®, Humira® and Herceptin®. The top 5 
brands had sales of over $ 5 billion each. However, besides that they often serve narrower 
disease phenotypes due to their specificity. The downsides of therapeutic proteins and 
monoclonal antibodies are that  
1. they are not consumable as pills 
2. logistics are more complicated due to their instability 
3. they are more expensive than small molecules.  
Although the market value of small molecule drugs which use one or more biocatalysis 
steps in their synthesis amounts to well over 30 billion US$ and is growing, the share of 
biotechnology is well below what it could be. The pharmaceutical industry is under great 
pressure due to exploding R&D costs, politically due to the health care cost burden and 
from the market side due to an expected reduction of growth from 7% to 3%.  
Both large and small molecules could face a technology gap and manufacturing bottlenecks 
to meet these production challenges. In both cases we need innovative, sustainable and cost-
effective production methods.  
The vaccine market is a special subset of the pharmaceutical market, in which innovative 
solutions are sought for cancer, infectious diseases (e.g. malaria), pandemics (influenza) or 
bioterrorism. The vaccine market of 20 billion US$/year is expected to grow to 35 billion 
US$ in five years. Unusual new solutions such as production in transgenic plants may be 
required to achieve the scale and price targets (Langer, 2011).  
The number of market introductions of small molecule pharmaceuticals or NCEs (New 
Chemical Entities) has been steadily decreasing since the late 1980s, whereas new 
therapeutic proteins and monoclonal antibodies have increased. To make things worse, 
small molecule drugs are positioned in markets that are becoming increasingly generic, 
thereby adding further pressure. The only small molecule drugs with an annual growth of 
over 10% were high potency drugs and to a lesser extent peptides. However, keeping 
healthcare costs under control will require efficient and affordable drugs, which are 
generally smaller entities without complicated and folded structures such as large proteins 
which need expensive production and logistics and can only be administered by injection.  
However, solutions of the manufacturing challenges in the pharmaceutical industry will 
also provide solutions for other markets.  
We need new cost-effective production for large and small molecule drugs (Meyer & 
Turner, 2009) with more chirality, more complex functionalities, and composed of various 
chemical structures. Examples are the glycosylation of proteins, aryl- or alkyl-organics 
drugs for modification of their biological efficacy and the functionalisation of novel 
biomaterials for medical devices and scaffolds for tissue generation using stem cells. The 
current biotechnological and chemical toolbox is reaching its technical limits and needs 
expansion to meet the economic and ecological manufacturing standards of the future 
(Meyer & Werbitzky, 2011).  
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Organism Genus, species Products Comment 
 
Prokaryotes 
 
 
Gram+ 
 
 
Gram- 
 
 
 
 
Bacillus 
Actinomycetes 
 
Escherichia coli 
Pseudomonas 
Gluconobacter 
Myxobacterium 
Small and large molecules 
 
 
Large molecules and enzymes 
Secondary metabolites 
 
Small and large molecules 
 
 
Secondary metabolites 
Generalists, well established technology, 
cost efficient, remains the standard method 
 
Host for secreted proteins 
 
 
The standard microbial workhorse 
 
 
Source of biologically active  
compounds but tricky to manufacture 
with 
 
 
Eukaryotes 
 
 
Fungi 
 
 
 
 
 
 
Algae 
 
 
 
 
Plants 
 
 
 
 
 
 
Protozoa 
 
 
 
 
Insect cells 
 
 
Mammalian 
cells 
 
 
 
 
Saccharomyces 
Pichia 
 
 
Penicillium 
Aspergillus 
 
 
 
Chlamidomonas 
 
 
 
 
Zea mais 
Nicotiana tabacum 
Pisum sativum 
 
 
 
Tetrahymena 
Trochoplusia 
 
Spodoptera 
Trochoplusia 
 
 
 
 
CHO , BHK1 
C127, NSO 
PerC6 
Stem cells 
 
hESC, iPS 
 
Large and small molecules 
 
 
Proteins and enzymes  
 
 
 
Secondary metobolites 
Citric acid, enzymes, proteins 
 
Mainly small molecules 
 
 
 
 
Small and large  molecules 
 
Bovine trypsin 
 
Different products 
 
 
 
 
 
 
Large molecules 
 
 
Large molecules 
 
 
 
 
Cells, tissues, organs 
 
Mostly specialist, niche applications with 
increasing importance 
 
Will lose its importance 
Uniform human like N-linked glycans, 
host for industrial enzymes 
 
Nutritional flexibility, efficient 
secreters, industrially widely used 
  
PUFAs, pigments, in discussion for 
biofuels 
Potential host for human antibodies, 
expression in 3 genomes 
 
Cost advantage, vaccines, 
“plantibodies” (antibodies) 
 
 
 
 
Expression system for ciliates for the 
production of therapeutic proteins 
 
 
 
Veterinary products, easier cultivation 
than mammalian cells 
 
Several pharma blockbusters, 
established technology 
 
 
Mouse cell lines 
Human cell line 
Tissue and organ repair, mass 
production in development 
Human embryonic stem cells, induced 
pluripotent cells  
1 Chinese hamster ovary cells, baby hamster kidney cells  
Table 3. This table gives an overview of all biological methods and frequently used genus 
which can be used for the production of small and large molecules. The microbial pro- and 
eukaryotes are further tabulated in Table 6. 
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3. The biotechnology toolbox 
Table 3 gives an overview of the production systems available today for the production of 
small and large molecules. Old technologies still dominate the industry, especially for 
pharmaceuticals. Other than pharmaceuticals still extracted from plants, animals (mostly 
now forbidden), only a few biotechnological methods are used. For example of the 130 
recombinant protein products in the US and European markets, 48 are expressed in 
microbes (34% E. coli specifically, 1% other bacteria, yeast 13%, see also Figure 6). Another 
43% of products are produced in mammalian cells, primarily in CHO cells. E. coli and CHO 
cells have the longest history of use since the commercialisation of the first recombinant 
proteins in the 1980s. CHO and E. coli account for 64% of the expression systems used in 
manufacturing of currently marketed recombinant therapeutics (US and Europe). Novel 
expression systems in evaluation for biopharmaceuticals include e.g. Pseudomonas 
fluorescens, Staphylococcus carnosus, Bacillus subtilis, Caulobacter crescentus, Chrysosporium 
lucknowense, Arxula sp. as we will see later. 
3.1 Cultivation options 
While Table 3 lists the organism which can be used, it does not include the cultivation 
methods which are listed in Table 4 below.  
 
Table 4. Overview of the principal biotechnological production methods. Fermentation in 
sterile containments is by far the most important and suitable for bacteria, fungi, protozoa, 
algae, plants cells, insect cells, mammalian cells. Stem cells are preferentially produced 
adherent in biofilms, but the mass production for therapeutic purposes will probably also 
use suspension culture.  
The standard manufacturing procedure in Table 4 is the submersed production of 
organisms in sterile containments as shown in Figure 1. This method allows the controlled 
growth of one organisms in a closed tank (fermenter). In over 15 years Armin Fiechter of the 
Swiss Federal Institute of Technology in Zürich developed a standardised biological test 
system and systematically tested many different bioreactor designs at the m3 scale. 
Although many new and interesting bioreactor designs exist, nothing has really changed 
since the 1980s and the numbers prove that the classic stirred tank with Rushton impellers 
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remains the most versatile fermenter design (Meyer, 1987). It can be used for unicellular and 
filamentous cells, and is even used in large scale fermentation for mammalian and plant cell 
cultures. Moreover, the design gives good performance over a wide range of viscosities. It is 
a truly multipurpose equipment, with decades of depreciation times for the invested capital 
for the tanks themselves. The average cost for a large scale sterile fermentation plant 
(without down stream processing) ranges between 130000 €/m3 for an ISO plant to 300000 
€/m3 nominal volume for a cGMP plant for injectable products.  
The technology transfer and engineering challenges of fermentation, which include control 
of the physicochemical environment, mass and gas transfer and other items are discussed 
elsewhere (Sharma et al., 2011; Meyer & Klein, 2006; Meyer & Rohner, 1995; Meyer & Birch, 
1999; Hoeks et al., 1997). Table 4 is a very general overview and many variants of 
suspension cultures cannot be discussed here. For example the immobilisation of cells by 
filtration in combination with continuous culture is a powerful tool to reach outstanding 
productivities with mammalian and microbial cells if sterile operation can be achieved and 
the cell type allows extended number of cell divisions and generations Hoeks et al., 1992).  
  
Fig. 1. Left side: photograph of a 15m3 state of the art sterile containment for high cell density 
fermentations. LONZA has built and operates such high performance equipment up to the 
75m3 for a range of organisms including methylotrophic yeasts such as Pichia pastoris. The flow 
breakers are designed as cooling elements needed to remove metabolic heat. The stirrers are 
concave Rushton impellers which, in combination with specially designed dip pipes (not 
shown), allow optimal mixing. In most cases the stirrer configuration is completed by the use 
of a top radially downward pumping marine impeller. Right: Two chromatography columns 
for the purification of injectable therapeutic proteins with a diameter of 2 meters to 
demonstrate size and complexity of down stream processing (Copyright@Lonza).  
3.2 The production organisms 
The production strain is not everything, but everything is nothing without a good production strain. 
Irrespective of the organism used in suspension culture for biotechnological manufacturing, 
there are numerous common problems, but also some typical differences, which will be 
discussed. Strain development is, however, the key issue for a commercially viable 
bioprocess. We have seen above, that companies have invested in expensive multipurpose 
fermentation equipment. Thus, the biology must be adapted to existing equipment and not 
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the other way round. Table 5 summarises our experience with regard to the different factors 
influencing manufacturing costs with mammalian and bacterial cell cultures.  
Generally, the strain and its growth characteristics define medium composition, cycle time 
and final product concentrations. Consequently, the number of steps needed in downstream 
processing (DSP) and volumetric sterile productivity (the two key cost drivers) are directly 
related to the choice of strain. The ideal strain is genetically stable, has a high specific (qp) 
and volumetric productivity (Qp), forms no by-products, and uses a well-defined medium 
resulting in a DSP with a limited number of steps. Fermentation is where value is created, 
downstream processing needs to conserve that created value.  
A key issue in achieving a high specific and volumetric production rate is the choice of a 
highly efficient expression system and finally choosing the right recombinant strain for 
production.  
 
Table 5. Effect of strain, process and plant on the overall process outcome. A highly 
productive strain is the most important factor in a bioprocess. I & D = Interest & 
depreciation. Y = Yield.  
3.2.1 Prokaryotes and lower eukaryotes 
3.2.1.1 Bacteria, yeast and fungi 
Prokaryotes such as bacteria and lower eukaryotes such as yeasts or fungi are by far the 
most productive organisms in biotechnology. We will call them collectively 
microorganisms in this paper. Because of their small size (Figure 2), microorganisms have 
by far the largest surface to volume ratio in the living world which allows them to 
maximize their metabolic rates because of a high rate of exchange of molecules through 
their surface. With the right cultivation conditions, microorganisms grow exponentially 
according to the equation  
Xt = Xo * e(μ * t)  
Xo is the biomass concentration at time zero, or the start of cultivation. Xt is the biomass 
concentration at the time of harvest. μ is a strain specific growth rate. Some of the fastest 
growing bacteria weighing maybe 10-12 g are theoretically able to duplicate and grow so fast 
that their biomass would reach the mass of the earth (9 *1054 tons) in less than a week. This 
means, that if a bacterial strain produces a protein or another product which can be 
industrially applied, large amounts can theoretically be produced economically. 
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Not only are microorganisms able to increase biomass at breathtaking rates, many are also 
able to grow under different conditions and on a great variety of substrates. This metabolic 
flexibility requires the ability to produce thousands of different enzymes and other proteins 
for all sorts of reactions and purposes. With the advent of genetic engineering, these 
enzymes and proteins can be overproduced in great quantities. Today entire pathways are 
modified and completed with heterologous genes, which allows the expression and 
production of molecules foreign to the species. 
   
Fig. 2. Left a budding cell of the yeast Saccharomyces cerevisiae. During the reproductive phase a 
cell multiplies by forming buds. After the buds enlarge, nuclear division occurs and a cross 
wall is formed between the two cells. S. cerevisiae is easy to cultivate at large scale and it serves 
as host in many biotransformation processes, mainly after genetic recombination. The 
photograph in the center shows a few cells of the workhorse par excellence in biotechnology: 
Escherichia coli. The diameter of the E. coli cells varies between 0.5 and 1.5 micrometer. The 
bacterium to the right belongs to the genus Rhizobium, of which the strain HK1349 is used at 
large scale for the production of L-carnitine (Copyright@Lonza).  
However, it does not end with the ability of microorganisms to produce large amounts of 
biomass and a great variety of different enzymes and proteins in a short time. There is an 
even more important reason why one wants to use microorganisms, namely the chemo-, 
regio- and enantio-selectivity of the microbial toolbox, and this is true for all living matter. 
No chemical manufacturing technology can match the precision of natural systems for the 
production of chiral and complex small and large molecules.  
While this article focuses on the production of recombinant proteins and small molecules 
with Escherichia coli, it is important to understand the advantages of the different expression 
and production systems and compare them with the work-horse Escherichia coli.  
There are now such a multitude of microbial host and expression systems theoretically 
available (Meyer et al., 2008) that it becomes difficult to choose the right combination. 
Emerging alternative production systems including those for glycosylated 
biopharmaceutical proteins for therapeutic use also are numerous (Jostock, 2007). Escherichia 
coli is currently the almost exclusively used prokaryotic production system but alternatives 
in discussion and developed on top of the commercially available expression systems are 
listed in Table 6. Examples are Caulobacter crescentus, Proteus mirabilis, Pseudomonas strains, 
Staphylococcus carnosus, Streptomyces, as well as fungi and yeasts such as Pichia, Hansenula, 
Arxula, Yarrowia, Aspergillus or Trichoderma. 
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 Name Microorganism Commercial Source 
 
Bacillus megaterium 
XS TechnologiesTM, Bacillus 
Bacillus subtilis (superoxidizing strains) 
PurePro Caulobacter expression system 
Clostridium Expression System 
Corynex 
Clean genome, stripped down E. coli  
XS TechnologiesTM, E.coli 
PaveWay ProTM  
ESETECTM 
Glycovaxin Bioconjugates 
pET System 
Flavobacterium heparinum 
Lactococcus lactis 
Methylobacterium extorquens 
Pseudoalteromonas haloplanktis 
PfenexTM 
Ralstonia eutropha 
Staphylococcus carnosus 
Streptomyces 
Cangenus, Streptomyces 
C1 Expression 
NeuBIOS Expresison 
Neurospora Expression 
Arxula adeninivorans Expression 
Hansenula Expression 
Hansenula polymorpha Expression 
Kluyveromyces lactis 
XS TechnologiesTM 
Pichia pastoris 
Pichia pastoris 
GlycoFi Technology 
Saccharomyces cerevisiae expression 
ApoLife Yeast Expression 
EASYEAST 
Zygosaccharomyces bailii 
 
 
Bacillus megaterium 
Bacillus subtilis 
Bacillus subtilis 
Caulobacter 
Clostridium botulinum 
Corynebacterium glutamicum 
Escherichia coli  
Escherichia coli  
Escherichia coli  
Escherichia coli  
Escherichia coli  
Escherichia coli  
Flavobacterium heparinum  
Lactococcus lactis 
Methylobacterium extorquens 
Pseudoalteromonas haloplanktis 
Pseudomonas fluorescens 
Ralstonia eutropha 
Staphylococcus carnosus 
Streptomyces 
Streptomyces lividans 
Chrysosporium lucknowense 
Neurospora crassa 
Neurospora crassa 
Arxula adeninivorans 
Hansenula polymorpha 
Hansenula polymorpha 
Kluyveromyces lactis 
Pichia pastoris 
Pichia pastoris 
Pichia pastoris 
Pichia pastoris 
Saccharomyces cerevisiae 
Saccharomyces cerevisiae 
Saccharomyces cerevisiae  
Zygosaccharomyces bailii 
 
 
Technical University Carolo 
Lonza 
University of Groningen 
Research Corporation Techno
Wisconsin Alumni Research F
Ajinomoto 
Scarab Genomics LLC 
Lonza 
Avecia 
Wacker Biotech 
Glycovaxin 
Novagen 
BioMarin Pharmaceutical Inc 
GTP Technology S.A., NIZO
National Research Council of
University of Naples 
Dow Chemical Co. 
Dartmouth College 
Boehringer Ingelheim Pharma KG 
Plant Bioscience Ltd, Tsukuba Industria
Cangene Corp. 
Dyadic International Inc. 
Neugenesis Corp. 
Genencor International 
Pharmed Artis GmbH 
Rhein Biotech Ltd, Artes Biotechnology GmbH 
Artes Biotechnology GmbH 
DSM Biologics, New England 
Lonza 
Research Corporation Techno
Alder Biopharmaceuticals 
GlyocoFi, Merck 
Delta Biotechnology Ltd. (No
ApoLife 
Biomedal, S.L. 
University of Milano Bico
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Fig. 3. The fungus Aspergillus niger is a “generally recognised as safe” (GRAS) organism 
used industrially for the production of many substances such as citric acid or gluconic acid, 
enzymes (e.g. glucose oxidase, glucoamylase, alpha-galactosidase) and other compounds. It 
is also a versatile host for the heterologius expression of proteins (Copyright@Lonza). 
Aspergilli (Figure 3) are ideally suited for recombinant protein expression as they have an 
enormous nutritional flexibility combined with a particularly efficient secretion system and 
secretion capacity (Fleissner & Dersch, 2010). They are amongst preferred organisms for the 
production of commercial food enzymes. Genetic engineering of different Aspergillus host 
strains has also allowed the synthesis of industrially relevant amounts of various 
heterologous proteins (such as human lactoferrin, calf chymosin or the plant-derived 
sweeteners thaumatin or neoculin peptide sweeteners, Nakajiama et al., 2008). Proteins are 
also efficiently glycosylated in Aspergilli, while undesired hyperglycosylation is usually not 
observed. Whole genome sequences of several Aspergillus species are now available.  
3.2.1.2 Algae 
Recently, Chlamydomonas reinhardtii, a unicellular eukaryotic green algae has been proposed 
as a host to produce several forms of a human IgA antibody directed against herpes simplex 
virus (Franklin & Mayfield, 2005; Specht et al., 2010). The main reason for turning to algae is 
the claimed cost advantage and the absence of viral or prion contaminations that can harm 
humans. One can frequently read that microalgae grow faster (by an order or two of 
magnitude!) than terrestrial plants and biomass titers of 600-1000 mg/l dry weight are 
reached. However, one has to be careful. Microalgae can grow very fast when grown 
heterotrophically on glucose for example. In this case the performance of high cell density 
fermentations are almost as productive as those reported for bacteria and yeasts (Xiong et 
al., 2008). But things look different when microalgae are mass-produced phototrophically! 
For a number of technical and biological reasons not discussed here, doubling time of 
around 10 hours are probably a realistic assumption, leading to growth rates of μ= 0.07 per 
hour. This is very low when compared to the bacterium Escherichia coli where growth rates 
of 1 and higher are quite common in large scale. But growth rates are perceptibly higher 
than with all other eukaryotes except the yeasts and fungi mentioned above. The advantage 
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over terrestrial plants is the smaller amount of soil used which leads to much better 
productivities per hectare for algae.  
Algae might also have some other distinctive features, which could give them an advantage 
over other expression system for selected products. For example all three genomes 
(chloroplast, mitochondrial, nuclear) have been sequenced and can be transformed and each 
has distinct transcriptional, translational and post-translational properties. Proteins can 
accumulate at particularly high levels in the chloroplasts because of the absence of the 
silencing mechanisms. However, proteins in the chloroplasts are not glycosylated. Another 
feature of algae is, that they can be grown using sunlight or heterotrophically, or using a 
combination of both. 
  
Fig. 4. Polyunsaturated fatty acids (PUFAs) such as docosohexanoic (DHA) acid are 
important building blocks of human brain tissue or the retina of the eye. The molecule can 
be produced by fermentation of marine algae. The picture shows the algae Ulkenia sp. which 
is used for the industrial production of DHA. They grow to form “footballs” consisting of 
single cells – 5 in this case with the product accumulated in the cells as oil drops. The size of 
the “football” is about 2 μm. Picture by Stefan Geimer, University of Bayreuth, Germany for 
Lonza (Copyright@Lonza).  
The reality is that algae are routinely used for the production of polyunsaturated fatty acids 
only, and that other small molecule products such as carotenoids (Fernández-Sevilla et al., 
2010 ) are merely in discussion. Although their growth is slow when compared to microbes, 
algae grow faster than terrestrial plants especially when grown heterotrophically with sugar 
as carbon and energy source. However, large-scale mass cultivation of algae using sunlight 
is far from being solved, and the calculations are sobering. Algae using CO2 as a carbon 
source are a theoretically ideal solution but are a long way from being cost-competitive in 
practice (Van Beilen, 2010).  
Whether algae will ever play a role for recombinant protein production and especially for 
recombinant monoclonal antibodies is very doubtful for two reasons. Firstly, the industry is 
very risk averse, conservative and one does not want to change well established production 
systems. Secondly, there are microbial systems being successfully developed which are also 
able to provide human-like post translational modifications as we will see later.  
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3.2.2. Higher eukaryonts 
3.2.2.1 Plants 
Whole plants. Pharming or molecular farming describes the use of transgenic plants 
(potato, tobacco, banana, tomato, maize, rice, lettuce) and animals for the production of 
recombinant therapeutic proteins or other recombinant drugs. As with algae, the driver to 
use plants for recombinant proteins and monoclonal antibodies is the lower unit cost of 
agricultural production combined with easy scalability while post-translational 
modifications are possible (Ahmad et al., 2010).  
Starting in the late 1980s human interferon, mouse immunoglobulins and human serum 
albumin were the first recombinant proteins to be tested for transgenic plant production. 
The first molecular farming project was in 1999 to trigger an immune response in humans 
with a safe and cost-effective edible vaccine (Langer, 2011). By 2007, about 370 plant made 
pharmaceuticals (PMPs) were undergoing field trials and about 16 of them were reported to 
be in clinical trials (Spök, 2007). Recombinant plants are an interesting form of production, 
and we see important differences to algae.  
1. If the product is in an edible form (for example in seeds or fruits) formulation may not 
be necessary 
2. the product in plant material will be easily and stably stored and  
3. logistics can be easier as cooling may not be needed for storage and transport. 
Because of the cost advantage, it is claimed that insulin could be a candidate for transgenic 
plant production as diabetes becomes a globally widespread disease, where affordable 
insulin is an absolute necessity. Vaccines in particular can be interesting products for plant 
made therapeutic proteins and other pharmaceuticals. MEDICAGO has developed a plant-
based manufacturing platform (Proficia vaccine and antibody production system) with 
PHILIP MORRIS that produces (proficia) vaccine doses (H5N1 flu) in Nicotiana benthamiana 
leaf cells, a wild Australian relative of cultivated tobacco (Vécina et al., 2011). It is a transient 
expression system based on Agrobacterium tumefaciens, infecting plant cells and transferring 
genetic information to leaf cells. 600 million US$ have been invested in NOVARTIS plant 
R&D facilities with 167 acres of land. SIGMA ALDRICH uses molecular farming to make 
avidin, aprotinin, lysozyme, lactoferrin and trypsin at small scale for use as chemicals. 
TrypZeanTM of SIGMA ALDRICH FINE CHEMICALS is a commercial recombinant bovine 
trypsin from transgenic corn.  
Plant seeds are also being investigated as bioreactors for recombinant protein production 
(Lau & Sun, 2009), because they naturally contain large amounts of proteins but have low 
protease activities and low water content. Antibodies, vaccine antigens and other 
recombinant proteins have been shown to accumulate at high levels in seeds and remain 
stable and functional for years at ambient temperatures. As seeds can be eaten they allow 
oral delivery of vaccine antigens or pharmaceutical proteins for immunisation where oral 
delivery is an option. Unfortunately, most protein based therapeutics are usually not 
biologically active after oral consumption.  
However, recombinant production of, for example, proteins in genetically modified plants 
has also several drawbacks. 
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1. The time to create a stable transgenic host 
2. low protein titers  
3. extraction and purification from plant organs (if needed) 
4. non mammalian type glycosylation.  
Plant transformation using physical methods is rather inefficient (gene gun). Transient 
expression is less time consuming but limited in scale. Recombinant Agrobacterium 
tumefaciens or plant viruses like the tobacco mosaic virus are used for transient expression.  
Let us consider growth rates and use rapeseed as an example as it is one of the 
industrially used genetically modified crops. At the end of August one hectare is 
inoculated with 3-4 kg of rapeseeds. At the end of July in the following year (the plant 
needs a cold period to thrive – the so called vernalisation) the same hectare yields on 
average 4000 kg of seeds, from which 1700 l of rapeseed oil can be extracted. The biomass 
has increased by a factor of 1000 in 11 months. This represents a growth rate of μ = 0,05 h-1 
when calculated for the seeds growing on one hectare. This is relatively high, but it 
should be considered that one uses 1 hectare during one full year to produce 1’700 l of oil. 
Using heterotrophic algal fermentation probably 2000 times more oil could probably be 
produced on the same hectare. But then again, one still needs hectares to produce the 
necessary carbon and energy source for the fermentation, and we are thus back to square 
one with algae.  
Coming back to transgenic plants and recombinant proteins: because of strong negative 
pressure from non-governmental environmental organisations and consumer organisations, 
transgenic plants in general will be slow to be used, also for the manufacturing of 
therapeutic proteins, unless they offer some of the advantages mentioned, such as edible 
and cheap recombinant drugs and vaccines for example.  
Plant cell culture. An alternative to grow whole plants is to grow plant cells in 
suspension cultures. GREENVAX produces influenza vaccines by growing tobacco using 
XCELLEREX XDR single use bioreactors. GREENOVATION (Greenovation 2011) 
proposes bryotechnology (bryophytes = mosses) for recombinant protein production. 
PROTALIX’s BIOTHERAPEUTICS Inc produces the enzyme replacement drug 
taliglucerase alfa for the treatment of Gauchers disease in disposable 800 litre bioreactors 
with carrot cells. Despite the fact that large companies such as PFIZER also stake a claim 
in plant cell-made biopharmaceuticals (taligurase alfa in carrot cells against Gaucher’s 
disease of PROTALIX, Ratner, 2010), we conclude that commercial heterologous protein 
production in transgenic plants will not be economically relevant in the foreseeable 
future.  
Whole plants and plant cell suspension culture, both will not play a relevant role in the 
production of therapeutic proteins and monoclonal antibodies. However, as with whole 
plants the situation is a different one for the recombinant production of other products and 
molecules such as secondary metabolites. The shift of wealth from west to east and north to 
south will fortunately eliminate economic inequalities. But an increasing global prosperity 
also increases pressure on naturally sourced raw materials especially from plants. Plant cell 
culture, recombinant or not, is a great alternative and will help to relieve pressure on partly 
even endangered species.  
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3.2.2.2 Protozoa 
Heterologous expression of proteins or protein fragments is also possible in protozoa. 
Dictyostelium discoideum (Han et al., 2004), Leishmania tarentolae, Perkinsus marinus and 
especially Tetrahymena thermophila are organisms used, for which recombinant protozoa 
techniques exist. The ciliate-based expression system (CIPEX) of CILIAN AG (Cilian, 2011) 
is a proven tool which makes protozoa a potential competitor of mammalian cells such as 
CHO cells. For example viral influenza haemaglutinin, parasite surface proteins and a 
human intestinal alkaline phosphatase and a human DNase I were expressed and secreted 
in the unicellular non-pathogenic protozoan ciliate Tetrahymena thermophila (Hartmann et al., 
2010; Aldag et al., 2011). The genome of Tetrahymena thermophila is entirely sequenced, and it 
is one of the best-characterized unicellular eukaryotes as it has served for long time as a 
laboratory model in biology.  
Protozoa are naturally mostly feeding on bacteria. However, they can also easily be grown 
by pinocytosis in a culture medium containing only soluble components. Growth rates of 
protozoa in non-optimized media and culture conditions reach values of μ = 0.02 h-1 and 
viable cell densities of 1 x 107 ml-1. Protozoa can also be cultivated in normal continuously 
stirred tank bioreactors and possess the sub-cellular machinery to perform eukaryotic post-
translational protein modifications. However, protozoan-based expression systems have not 
yet made the transition from a laboratory model to an established recombinant protein 
platform at large scale. The main advantage of protozoa is that they are free of endogenous 
infectious agents as their genetics and phylogenetic distance to higher animals make viral 
infection unlikely. As with other expression systems high gene doses allow relatively high 
volumetric productivities [Qp] and scale-up has been proven up to the 1.5 m3 scale. Protozoa 
have a consistent oligo-mannose N-glycosylation albeit not of mammalian nature.  
 
Fig. 5. Picture of Tetrahymena thermopile, one of the best characterized unicellular non-
pathogenic protozoa, expressing a recombinant green fluorescent protein in phagosomes; 
protozoa can also secrete recombinant products. The ciliates, distributed on the cell surface, 
cannot been seen because the photograph was taken with a light microscope. The cell 
measures about 50 μm in diameter (Copyright@Cilian).  
In the case of Tetrahymena thermophila (Figure 5) and with optimized media and culture 
conditions, cell densities of over 2 x 107 cells per milliliter and dry biomass titers of 8 g/l can 
www.intechopen.com
Microbial Expression Systems and  
Manufacturing from a Market and Economic Perspective 
 
227 
be reached in high cell density protozoa fermentations and 50 g/l in continuous 
fermentations with cell retention. Generation times become very short and values between 
1.4 and 3 hours can be obtained. 
In conclusion, protozoa such as Tetrahymena thermophila have a certain potential for the 
recombinant production of selected recombinant proteins. To some extent they combine the 
advantages of the microbial and the mammalian world as they can grow rapidly to 
relatively high cell densities and have a posttranslational modification apparatus. If the 
necessary tools for the manufacturing with stable expression, conserved sequences and 
target glycosylation can be established, we may see cultivation of protozoa in large scale 
fermenters in the future for human enzymes, monoclonal antibodies and, in particular 
protein vaccines. Because of their faster growth, the first vaccine targets in preclinical phase 
are already in development using protozoan recombinant expression.  
3.2.2.3 Insect cells 
Insect cells culture. A few recombinant proteins made using insect cell lines have already 
been approved for veterinary use. Only one vaccine, Cervarix® of GLAXO SMITH KLINE, 
has been approved for human use within the EU (in 2007) and in the US in 2009. Production 
with insect cells has the following advantages: 
1. easy to culture and faster than many mammalian cell lines 
2. high tolerance of osmolality 
3. advantageous and low ratio by-product vs expressed product 
The Spodoptera frugiperda cell lines (Sf-9 and Sf-21, Figure 6) and Trichoplusia ni are frequently 
used host cell lines for recombinant protein expression and production via infection with a 
genetically modified baculovirus expression vector system, BEVS (Invitrogen, 2011; 
Quiagen, 2011; Tiwary et al., 2010). As for other cell lines used for production, insect cell 
lines need to be “immortalized” or rendered permanent.  
 
Fig. 6. Cells from the ovarium of this moth Spodopera frugiperda are used in combination with 
baculoviruses for the recombinant production of proteins in suspension culture in 
fermenters. The method was first introduced in 1982 and in 1985 the first recombinant 
protein interleukin-2 was expressed in moth cells (Copyright@Canadian Biodiversity 
Information Facility, 2011).  
www.intechopen.com
 Innovations in Biotechnology 
 
228 
Taticek et al. (2001) compared the growth and recombinant protein expression in suspension 
culture and attached cells culture of Spodoptera frugiperda and Trichoplusia ni (Taticek et al., 
2001) expressing Escherichia coli beta-galactosidase or human secreted alkaline phosphatase. 
The production of both enzymes varied as a function of inoculum size, media, culture 
conditions etc. Cell densities of 5 x 106 viable cells/ml and doubling of 20 hours were 
reached, which corresponds to a growth rate of about μ = 0.04 h-1. It is not clear whether a 
typical large scale fed batch cycle for insect cells would also be around 4 to 5 days which 
would about 2 to 3 times faster than a batch with mammalian cell culture. However, 
generally insect cells have two major disadvantages: 
1. the baculovirus system results in cell death and lysis of the host insect cells and the 
release of cell proteins, which offsets again the high productivity of the cells 
2. N-glycosylation of insect cells is different from mammalian cells. 
Vermasvori et al. compared the production of a model protein (Negative factor or Nef) in 
Escherichia coli, Pichia pastoris and the Drosophila S2 cell line (Vermasvuori et al., 2009). When 
studying the systems purely economically the microbial system had significantly lower 
manufacturing costs than the insect cell lines. The most significant difference between the 
manufacturing costs of the two microbial systems was due to the much longer strain 
construction time with the Pichia pastoris. The manufacturing costs for the production of 100 
mg Nef protein were  
1. Escherichia coli 6456 € 
2. Pichia pastoris 13382 € 
3. Drosophila S2  21111 € 
Omitting the strain construction costs, the microbial systems were cost-wise fairly 
comparable. These numbers from small scale experiments insinuate that insect cells could be 
theoretically a threat for mammalian cell culture. However, there are no compelling data 
showing an advantage by switching to insect cells for large scale production.  
Transgenic insects. The production of recombinant proteins in live animals is an option, as 
production of therapeutic proteins and monoclonal antibodies is an option in living plants. 
The most frequently proposed method is that of producing and extracting recombinant 
proteins from the milk of transgenic livestock. However, insects such as silkworms (Fraser & 
Jarvis, 2010), can theoretically also be used for recombinant protein production. However, 
we believe that transgenic insects will not play a role in the production of pharmaceuticals 
rather than in the control of insect populations and prevention and control of parasites and 
disease transmission in man, animals and plants.  
3.2.2.4 Mammalian cells 
Mammalian cells in culture. The clinical and commercial success of mainly monoclonal 
antibodies has led to the rapid development of mammalian cell culture within a short time 
after the landmark findings of Cesar Milstein and Georges Köhler in the mid 70s. 
Mammalian cell culture is a well established production method for the production of 
therapeutic proteins and monoclonal antibodies. One of the most frequent mammalian hosts 
used is the CHO cell line (Chinese hamster ovary) in combination with the GS expression 
system or the DHFR (dihydroolate reductase) expression system (Birch & Racher, 2006). The 
mouse NS0 cells cell line is another option which is less frequently chosen today. 
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Continuously stirred tank fermenters are operated (Varley & Birch, 1999) with volumes of 
up to 20 m3. An average batch lasts about two weeks with specific productivities up to 100 
pg/cell x day. Product titers for antibodies of several grams per litre are almost routine 
today, making product recovery and purification the greater challenge from a 
manufacturing perspective. Defined media are available for high growth rates, stable 
expression, low lactate and byproduct formation to facilitate fermentation, isolation and 
purification. Lonza (Lonza, 2011) recently introduced a novel medium and feeding platform 
for its GS-expression systemTM, which leads to product titers of up to 10 g per litre!  
Rapid and efficient development of stable production cell lines is a critical step and 
transfection alternatives for the quick preparation of stable mammalian production cell lines 
for recombinant proteins are needed (Wurm, 2004; Birch et al., 2005). The PiggyBac 
transposon is an example of a novel delivery vehicle for rapid and efficient recombinant cell 
line generation (Matasci et al., 2011).  
Unfortunately, the generation of a stable production cell line remains a time consuming 
endeavour. However, for early feasibility tests with a protein, transient gene expression and 
protein production may be sufficient (Ye et al., 2009). EXCELLGENE SA (Excellgene, 2011) 
has successfully established transient gene expression for fast protein delivery. Production 
and recovery of several grams of purified protein can be done within 3-4 weeks. However, 
transient recombination is limited by two factors: 
1. the need for large amounts of plasmid DNA for transfection 
2. the requirement for cell culture medium exchange before transfection 
Nevertheless, transient technology allows a reduction of cost and time for 
biopharmaceuticals with mammalian cells. It is not yet a valid method for regular 
production or even material for clinical material testing of e.g. drug candidates. Cell lines 
may not be stable but at least production can start within a matter of weeks. The 
combination of transient expression with disposable reactors, which are now available up to 
the m3 scale (Eibl et al., 2010), makes the production of several 100 g of new proteins 
possible in a short time.  
Transgenic animals. Clones and transgenics of livestock and companion animals have 
become a reality in animal farming, meat production and even pharmaceutical production 
since the first transgenic animals were created in the laboratory. Mice were the first 
mammals to be genetically modified in the early 1980s and in 1987 the breeding of a tPA 
(human tissue plasminogen activator) producing transgenic mouse was reported by Simons 
et al. (1987). As with any other organism mentioned above, it is also possible to introduce or 
delete existing genes in an animal cell and have the modification passed on to the next 
generation resulting in a new phenotype of the living animal.  
In 2004 about a dozen companies had products in development in transgenic animals 
(Keefer, 2004) but many of them have been abandoned. Human antithrombin III (hAT) of 
GTC BIOTHERAPETICS, a glycoprotein controlling blood clotting, was the first approved 
biopharmaceutical from transgenic animals. NEXIA BIOPHARMACEUTICALS published a 
patent in 2002 for the production of spider silk biofilaments in transgenic animals using milk 
or urine-specific promoters (Karazas & Turcotte, 2003) but the process is not competitive 
with microbial production. The Dutch company GEN PHARMING was a pioneer in the 
field of production of human lactoferrin in ruminants. Alpha 1-antitrypsin, fibrinogen, 
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tissue plasminogen activator, vaccines, human monoclonal and polyclonal antibodies are 
other example of products.  
This technology has, however, been the subject of controversial discussions (for example 
“cloned meat”) as these biotechnology applications have been judged with evident 
hierarchies of acceptability (Einsiedel, 2005). Transgenic animals are particularly sensitive 
but they nevertheless offer options to produce a therapeutic protein in a fluid of the animal 
(milk, blood, urine) of mice, goats or cows. Coupling the target protein to a signal one can 
direct the expression into the mammary glands and milk - the optimal choice.  
Nonmammalian animals such as birds or insects (see above) can also be used for the 
production of glycosylated therapeutic proteins and monoclonal antibodies, especially in the 
egg white or egg yolk of transgenic chicken.  
Patel et al., 2007 claim, that animals are more cost effective bioreactors, with 16 therapeutic 
proteins in development in transgenic animals (sheep 5, pig 2, goat 4, cow 5) plus several 
monoclonal antibodies in cows, goats and chicken. Productivities in terms of milk 
containing recombinant protein given are ~8000 litres containing a total 40 – 80 kg of 
recombinant protein. However we disagree, and think that transgenic animals will only be 
used in a very few and exceptional cases for the following reasons: 
1. low success rate of gene transfer (e.g. 0,1% with cows)  
2. cost and time to produce transgenic animals 
3. possible infectious agents from mammals  
4. low consumer acceptance in view of better alternatives 
5. many alternatives exist 
Take productivity as one example, a single cow will produce ~60 kg of a therapeutic protein 
in one full year which has still to be isolated and purified. In the case of a goat or a sheep 
that number drops to 4 kg and 2.5 kg per year, respectively. This should be compared with 
the productivity of a 20m3 bioreactor with mammalian cells which produces on average 125 
kg in a single month! That means one bioreactor replaces 25 cows, 375 goats or 600 sheep.  
How do depreciations between 25 cows and a 20m3 plant differ? The cost of one transgenic 
animal is high, 500000 US$ for one calf according to Keefer (2004). This is due to 
inefficiencies in this technique as over 1000 bovine, 300 sheep and 200 goat oocytes must be 
injected. Goats and sheep with their shorter generation interval are less costly, and the 
figures may look somewhat better today. On the other hand and based on numbers given by 
Patel et al (2007), we calculated an average of about 50000 US$ in value created per animal 
and per year. It now all depends how fast a productive herd can be created by cloning and 
how long the productive period of a cloned transgenic animal is? Over how many 
productive years do we have to depreciate the animals? One important disadvantage of a 
capital investment in a transgenic cow is that a cow is a dedicated “plant” while a bioreactor 
is a multipurpose and multiproduct installation.  
We do not believe that transgenic animals are an attractive alternative except for a few very 
special exceptions. However, the one argument for transgenic animals (as for transgenic 
plants and plant seeds) is the case in which the product can be consumed directly with the 
milk. It would make therapy affordable, and one can imagine that an oral protein-based 
vaccine would be an ideal candidate for a transgenic animal.  
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Fig. 7. Microbial and mammalian cell culture are used in 93% of all cases for the production 
of therapeutic proteins. See also Figure 8 with the spread of the individual expression 
systems. 
In summary, microbial fermentation and mammalian cell culture will continue to carry 
the main burden for the production of recombinant proteins as it is already the case today 
(Figure 7). Other expression systems, especially plant-based and algae, will have potential 
for recombinant protein niche applications. The situation is different for small molecule 
pharmaceuticals, neutraceuticals and fine chemicals, where a more varied host-expression 
system combination will be needed. However, even in the latter case one will first fall 
back on proven methods. We will now describe in more details the beacon in recombinant 
microbial expression – Escherichia coli.  
4. Escherichia coli as work horse 
In the year 1885 the German paediatrician Theodor Escherich (1857-1911) described a 
bacterium, which he called “Bacterium coli comunale”. At that time nobody could anticipate 
that this bacterium, which later on was named after him Escherichia coli, would become 
world famous as a model organism in the field of molecular biology and as “the” 
minifactory for recombinant protein manufacturing (Piechocki, 1989). 
This is best demonstrated by statistical figures related to expression platforms in use (Figure 8). 
In the reported year 34% of all recombinant therapeutic proteins registered in the US and EU 
were produced by means of Escherichia coli based expression technology. The second and third 
most successful expression platforms were Chinese Hamster Ovary cells with a 30% and yeast 
systems, mostly Sacharomyces cerevisiae, with a 12% shares respectively (Rader, 2008).  
4.1 Why is Escherichia coli such a popular expression host? 
Although there is no gold standard platform in microbial expression, expression systems 
based on Escherichia coli have dominated microbial expression for more than 30 years. One 
can only speculate on the reasons for this domination. Escherichia coli and its phages were 
early objects and models for studying molecular biology topics, especially aspects related to 
the understanding of gene functions and regulation. More than 10 scientists received the 
Nobel prize for exciting discoveries connected to research on Escherichia coli (Piechocki, 
1989). Worth mentioning is the isolation and purification of a restriction enzyme for the first 
time by Werner Arber in 1968. These enzymes are enabling tools in the area of rDNA 
technology. The rapid pace in the development of expression technology and of genetic 
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engineering tools is best reflected by the quite early launch of a first biopharma product, 
expressed in Escherichia coli, recombinant human insulin in 1982 (Humulin®, licensed by 
GENENTECH to ELI LILLY). This is even more remarkable if one considers the lengthy 
approval procedure for therapeutics. Escherichia coli based biotechnology profited directly 
from the multitude of fundamental discoveries made on this model organism, giving this 
species a timely technical advantage in use as expression host.  
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Fig. 8. Percentage of expression platforms used for the manufacture of bio-therapeutics in 
the US and the EU. The figure is based on numbers published by Rader (2008).  
Other explanations for the success of this microorganism are low genome complexity and 
the extra-chromosomal genetic elements, plasmids, which ease both (a) in-vitro 
manipulation of genetic elements and (b) insertion of homologous and foreign genes into 
the organism.  
Besides low safety concerns and high regulatory acceptance, ease of use and familiarity with 
the organism was in favour of Escherichia coli. There is hardly a student in biology who has 
not run at least one cloning experiment in one of the Escherichia coli expression systems used 
in academia. Since its first industrial applications, Escherichia coli expression technology has 
been continuously improved with the aims of gaining control of the quality of the 
recombinant products and increasing the product titre in fermentation, the latter obviously 
being crucial to process economy.  
4.2 What are the characteristics of an industrial Escherichia coli expression platform? 
Incremental improvements led to the development of Escherichia coli based expression 
platforms that are suitable for industrial use. More precisely these systems allow for 
robust, reliable and scalable processes and economical manufacturing. High performance 
expression technology is characterized by two properties: (a) high volumetric 
productivity Qp, preferentially due to a high specific product production rate qp and (b) 
high control on product quality, meaning that no or only a negligible amount of product 
variants are produced. 
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Industrial expression systems distinguish themselves from academic systems by an 
optimized combination of the various components of which an expression system is made. 
Basically, a bacterial expression system is composed of a host and a vector which contains 
the product coding DNA, a selection marker and various regulatory elements. Regulatory 
elements are promoters, signal sequences, ribosome binding sites, transcription terminators 
and vector replication or integration regions.  
Host. The host organism provides specific features to an expression system as a result of its 
genetic background; these features include:  
1. growth characteristics such as specific growth rate   
2. maximum achievable cell densities  
3. nutritional needs 
4. robustness at cellular and genetic level  
5. control of product degradation 
6. secretion capacity preferentially into the medium 
7. amount of endotoxins produced 
8. post-translational modifications  
High cell densities are most desirable since a positive correlation exists between the amount 
of biomass (X) and the product production rate (rp). The corresponding equation is  
 rp = qp * X (product production rate = specific product production rate x biomass).  
The relationship above should not be confused with growth rate dependency on the product 
production rate, which can be optimal at high or low growth rates. It is possible that in the 
worst case maximal specific production rates rp correlate with very low growth rate close to 
maintenance (Meyer & Fiechter,1985). In that case production requires two separate phases, 
growth and production phase. 
Commonly used Escherichia coli host strains are listed in Table 7. BL21 is the most frequently 
used Escherichia coli host. BL21 popularity is based on  
1. lon and ompT protease deficiencies  
2. beneficial growth and metabolic characteristics 
3. insensitivity to high glucose concentration. 
The organism is not sensitive to high glucose concentration due to its active glyoxylate 
shunt, gluconeogenesis and anaplerotic pathways and a more active TCA cycle, which leads 
to better glucose utilisation and lower acetate production (Phue et al., 2008). However, when 
used in combination with the T7 expression system and when exposed to stress, this host is 
at risk of bacteriophage DE3 excision. For this reason laboratories started to promote the use 
of BLR, a recA¯ mutant of BL21. In our experience an increased use of W3110 is taking place 
in the industry. This can be attributed to the excellent production capabilities of this host. 
Orgami strains may allow for better formation of disulfide bonds in the cytoplasm due to 
lower reducing power in the cytoplasm (Novagen, 2011). The endA¯ and recA¯ hosts DH5 
and JM109 are the organisms of choice for the manufacture of pDNA. The lack of 
endonuclease 1 which degrades double stranded DNA positively affects stability of pDNA 
(Phue et al., 2008). In conclusion, product nature and product characteristics determine the 
selection of the most optimal host.  
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Escherichia coli 
Host Strains 
Strain Characteristics 
 
BL21 
HMS174 
BLR 
Orgami strains 
Rosetta strains 
W3110 
MG1655 
RV308 
DH5 
 
 
B strain, lon and ompT protease deficiencies 
K-12 strain, recA¯  
B strain, recA¯ mutant of BL21 with decreased likelihood of excision of DE3 
K-12 or B strains with mutations in trxB and gor  
K-12 or B strains which supply tRNAs for codons that are rare in E. coli 
K-12 strain  
K-12 strain 
K-12 strain 
K-12 strain, recA¯, endA¯, often used for pDNA manufacture 
 
Table 7. Frequently used Escherichia coli host strains and related specific characteristics. 
Promoters. Promoters control the expression to the extent of how much and at which 
point in time mRNa is synthesized. As a consequence they control production of product. 
A large number of promoters that allow modulation of the mode of induction in a desired 
way are used in the industry. Lactose or lactose-analogue IPTG induced T7 promoter-
based expression systems currently dominate the market. Apart from T5, araB and phoA, 
other classical promoters such as lambda, lac, trp, PL, PR, tetA and trc/tac are rather 
seldom used.  
Novel promoters are under development and continuously make their way into industrial 
applications. New disaccharide inducible promoters, which induce protein production 
during the stationary growth phase, have recently been successfully applied in Escherichia 
coli based biopharmaceutical processes. Some of these are part of Lonza’s XS TechnologiesTM 
Escherichia coli platform, which has been chosen as an example to discuss performance of 
current leading industrial Escherichia coli expression platforms (Lonza). Depending on the 
promoter the induction signal is of a chemical or physical nature. Some of the above 
mentioned Escherichia coli promoters have been successfully used in other bacterial systems 
such as Bacillus subtilis (Alexander et al., 2007).  
State of the art industrial expression platforms allow for product specific modulation of the 
rate of protein synthesis. Proteins of high complexity, having disulphide bonds are typically 
best produced at a lower production rate. In contrast proteins of low complexity are often 
produced at a high production rate, thus achieving high concentrations after a short time of 
fermentation. Productivity is often affected by interaction between specific promoters and 
recombinant target proteins. Therefore, in general, it makes sense to screen for the 
performance of different promoters.  
Signal Sequences. Signal sequences determine whether a product is directed through the 
cellular membrane and out of the cytoplasma; the signal sequence is cleaved during the 
secretion step. Secretion is desirable in many cases, since a large proportion of target 
proteins do not fold correctly in the reducing cytoplasmic environment. Folding requires 
oxidative conditions which are provided outside the cytoplasm. Secretion sequences 
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frequently used in Escherichia coli are MalE, OmpA and PelB. Yeast organisms such as 
Saccharomyces, Pichia, Hansenula, Yarrowia and Gram-positive bacteria such as Bacillus and 
Corynebacterium secrete proteins which carry a secretion signal into the medium, whereas 
Gram-negative genera such as Escherichia, Pseudomonas and Ralstonia direct the product 
through the inner membrane into the periplasmic space. This is what the theory says. 
According to the authors’ experience, the Escherichia coli outer membrane is leaky for a large 
proportion of secreted proteins which are supposed to accumulate in the periplasmic space. 
The observed partitioning of the secreted protein between fermentation medium and 
periplasmic space can be influenced to some extent by modifying the fermentation conditions. 
The latter behaviour is product dependent and for the time being not predictable.  
Selection markers. Selection markers are necessary for the cloning process and crucial for 
controlling plasmid stability. Typical microbial selection markers are antibiotic resistance 
genes. However, the prevalence of β-lactam allergies strongly suggests avoidance of the use 
of ampicillin and other β-lactam derivatives for the purpose of selective pressure in the 
manufacture of clinical products. Optional stabilization systems used in Escherichia coli are 
based on antidote and poison gene systems with the poison gene being integrated into the 
bacterial chromosome and the antidote gene located on the plasmid, respectively (Peubez et 
al., 2010). Constitutive expression of the antidote gene stabilizes plasmid-containing cells. A 
system based on the mode of action described above is marketed by DELPHI GENETICS Inc 
(Delphigenetics, 2011).  
Besides the above mentioned regulatory aspect, Rozkov et al. (2004) note another one that 
should be taken into consideration when selecting the plasmid stabilizing system. 
According to these authors, the presence of an antibiotic selection marker imposes a huge 
metabolic burden on an expression system. They found that the product of the selection 
marker gene accounted for up to 18% of the cell protein. A negative effect on the 
recombinant expression of the genes of interest is highly likely. Due to constitutive 
expression this is the case even in the absence of the corresponding antibiotic in the 
medium. One way to circumvent this problem is to use complementation markers, i.e. 
marker genes that complement an auxotrophic chromosomal mutation.  
A majority of successful technologies, genetic elements and related know-how, are subject to 
patent protection or trade secrets, as shown also in Table 6. In particular, multiple license 
requirements for the use of a specific production technology can lead to an unfavourable 
economic situation. On the other hand, off-patent expression systems and elements thereof 
are usually not state of the art. Since process economy depends to a large extent on 
productive and robust strains, outsourcing strain development to a specialised laboratory is 
often justified, given that licensing cost remain reasonable. The resulting economic benefits 
on the process side typically offset the costs related to accessing a productive and robust 
state of the art industrial strain platform. 
4.3 A more critical view on Escherichia coli expression platforms 
Despite their dominant position within microbial expression Escherichia coli based 
expression platforms also exhibit weaknesses which should not be ignored. These 
drawbacks are shared with other commercialised Gram-negative expression platforms as 
Pseudomonas and Ralstonia. Among these disadvantages are  
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1. the presence of high levels of endotoxins that need to be removed from therapeutic 
products  
2. the difficulty of controlling full secretion into the medium.  
WACKER Chemie has commercialised a K-12 derivative that exhibits higher secretion 
ability than other K-12 and B strains (Mücke et al., 2009). Other expression system aspects 
such as:  
1. the lack of posttranslational modification capability including a lack of glycosylation 
machinery  
2. the capability of intracellular expression 
3. the difficulty of expressing complex, multimeric proteins with a high number of 
disulfide bonds  
are often referred to as disadvantages. These apparent drawbacks can, however, be turned 
to advantages depending on the target protein’s specifics.  
Table 8 compares the suitability of the 3 leading expression platforms related to 
characteristics of the expression candidate protein. Apart from the two characteristics (a) 
requirement for human-like glycosylation, which includes monoclonal antibodies whose 
efficacy depends on Fc effector functions and (b) peptide nature of the recombinant target, 
most of the aspects captured in the table, do not give a clear indication regarding choice of 
the ideal expression platform. There is a large grey zone which typically needs to be 
explored empirically.  
Active enzymes up to a size of 220 kDa and 250 kDa recombinant spider silk protein have 
been successfully expressed in Escherichia coli at high concentrations, questioning the dogma 
that bacterial systems are not suitable for the expression of large proteins. This thesis is 
further supported by successful expression of complex heterodimers, such as aglycosylated 
functional antibodies, in bacterial systems. For an in-depth analyis of expression of complex 
heterodimers in Escherichia coli we recommend the paper of Jeong et al. (2011). We also 
question the criticism towards inclusion body formation that often is cited as a 
disadvantage. Rather than a drawback we consider this as a capability that adds flexibility 
to the use of Escherichia coli based platforms. Industrial expression platforms allow for 
inclusion body concentrations as high as 10 g/l culture broth and above. This consideration 
combined with an efficient refolding process provides high potential for a competitive 
process from a cost point of view.  
Some therapeutic protein candidates are not glycosylated, such as a non-glycosylated 
version of an antibody. In particular, recombinant proteins produced by yeast expression 
systems may carry undesired O-glycans. In these cases a lack of glycosylation capability can 
be considered as advantage rather than a system weakness. Intracellular expression in 
Escherichia coli may lead to product variants (a) with N-terminal formyl-methionine and (b) 
without formyl-methionine at the N-terminus. Methionine cleavage by the methionyl-
aminopeptidase depends on the characteristics of the adjacent amino acid, which 
consequently determines the ratio of the 2 product fractions.  
Earlier on endotoxin formation and low control of secretion into the medium were 
mentioned as problematic aspects for expression systems which are based on Gram-negative 
bacteria such as Escherichia, Pseudomonas and Ralstonia. On the other hand Table 8 also 
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indicates some weaknesses of yeast platforms. On the one hand yeast N- and O-
glycosylation capability can negatively impact product quality so that adverse immunogenic 
reactions in the clinic are the result. Another problem often observed with Pichia and 
Hansenula are product variants produced through incomplete N-terminal processing and 
proteolytic degradation (Meyer et al., 2008). This, together with an on average lower 
observed productivity, negatively affects broad usage of yeast systems, despite their 
advantageous secretion capability.  
Protein Characteristics 
Bacterial 
(Gram-) 
Systems 
Yeast 
Systems 
Mammalian 
Systems 
 
size: small to mid size 
size: large proteins 
peptides 
 
monomers 
homo-multimers 
hetero- multimers 
disulphide bonds (folding) 
 
hydrophilic proteins (soluble) 
hydrophobic proteins (low solubility) 
 
human (like) glycosylated 
not-glycosylated 
 
Protein prone to proteolytic digest 
(N-terminal product variants) 
 
 
          
                  1) 
              2) 
 
          
          
           
                3) 
 
           
                4) 
 
           - 
           
 
           
  
 
 
          
           
            
 
           
           
           
           
 
           
            
 
                  5) 
            - 
 
                  6) 
 
 
  
   
- 
 
   
   
   
   
 
  
 
 
   
  
 
   
 
Table 8. Criteria that drive selection of an expression platform. Legend: –, not suitable;  
low,  medium,  high suitability; 1) mostly cited as limiting criterion, nevertheless, up 
to 220 kDa proteins have been expressed in Lonza’s E. coli XS TechnologiesTM platform with 
a very high titre, 2) Unigene and Lonza developed E. coli based peptide platforms, 3) secretion 
required for most recombinant proteins, 4) proteins exhibiting low solubility or a high 
aggregation propensity are often expressed at high titres as inclusion bodies, 5) yeast type 
glycosylation, mainly mannose comprising oligosaccharides, is highly immunogenic, 6) N-
terminal product variants are frequently observed with Pichia pastoris and Hansenula 
polymorpha as a result of incomplete N-terminal processing.  
Table 9 compares bacterial Gram-negative and yeast platforms to selected bacterial Gram-
positive expression platforms, i.e. to Bacillus and Corynebacterium platforms (White, 2011). 
The comparison suggests that the disadvantages of the existing bacterial Gram-negative 
platforms and yeast platforms can be overcome by moving into bacterial Gram-positive 
platforms. Gram-positive bacteria, in contrast to Gram-negative bacteria do not produce 
endotoxins and they naturally secrete proteins. Comparing them to yeast, they do not 
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glycosylate proteins and there are no N-terminal processing problems. Both Bacillus and 
Corynebacterium hosts need to be engineered to resolve the problematic aspects of the 
corresponding wildtype strains such as low plasmid stability and secretion of undesired 
proteases.  
Problematic 
Characteristics 
Yeast Platforms 
Pichia 
Hansenula 
Gram+ Platforms 
Bacillus 
Corynebacterium 
Gram- 
Platforms 
Escherichia 
Pseudomonas 
 
Endotoxins 
 
Control of secretion 
 
N-terminal product variants 
 
Undesired glycosylation 
 
suitable 
 
suitable 
 
not suitable 
 
not suitable 
 
suitable 
 
suitable 
 
suitable 
 
suitable 
 
not suitable 
 
not suitable 
 
suitable 
 
suitable 
 
Table 9. Suitability of yeast, Gram-negative and Gram-positive expression platforms related 
to classical microbial platform weaknesses.  
4.4 Production performance of relevant industrial Escherichia coli expression 
platforms 
In contrast to the expression of antibodies in CHO cells, expression success cannot be 
predicted in microbial expression systems. What is good for a specific recombinant protein 
A does not necessarily work for protein B, even if B is a protein variant of A. An integral 
part of the various strain platforms are generic high cell density fermentations. When 
considering industrialisation, strains and fermentation procedures should be looked at as 
single entities rather than separate process aspects. This is the main reason for the difficulty 
in judging the performance of expression platforms in general. Data from one single product 
are not sufficient, since the performance of one expression platform can differ greatly from 
product to product for as yet unknown reasons. One platform typically shows exceptional 
productivity only for a small number of products and rather low productivity for the 
majority of desired expression targets.  
Expression titres of commercial products are typically handled as trade secrets. The authors 
have access to an informative set of expression titre data of leading Escherichia coli 
expression systems which are part of Lonza’s XS TechnologiesTM platform (Figure 9). This 
platform is a broad one which in itself encompasses various Escherichia coli, Pichia pastoris 
and Bacillus subtilis platforms. In our experience, heterogeneity of the recombinant protein 
pipeline demands access to a variety of powerful expression tools in order to cope with 
specific expression challenges. On a few occasions the platform performance could be 
directly benchmarked against competitive CMO and other commercialised platforms based 
on Escherichia coli and Pseudomonas. On these occasions XS TechnologiesTM showed superior 
or equal performance. Therefore we consider the performance data shown in Figure 10 as 
representative for leading bacterial Gram-negative expression platforms.  
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Fig. 9. Example of an industrial expression platform, XS TechnologiesTM (Lonza). The 
platform comprises a number of powerful expression technologies for expressing 
recombinant proteins in Escherichia, Pichia and Bacillus in order to cope with the expression 
challenges related to the heterogeneity of the recombinant proteins pipeline, including 
recombinant peptides and pDNA.  
With Gram-negative organisms such as Escherichia coli and Pseudomonas, the recombinant 
product can be localized in different spaces, either intracellular (cytoplasmic) or 
extracellular. We define the latter as proteins expressed with a secretion sequence, and thus 
directed through the inner membrane, which means that the recombinant protein can be 
localized either in the periplasm or in the cell free medium. As a second aspect to consider, 
product is formed in either a soluble form or as insoluble aggregates. Apart from intentional 
inclusion body formation, production in a soluble, functional form is preferred. Therefore 4 
effective expression modes are to be distinguished. Recombinant protein can be localised 
(C1) in the cytoplasm, insoluble as inclusion bodies, (C2) in the cytoplasm in a soluble form, 
(C3) in the cell-free medium in a soluble form and (C4) in the periplasm in a soluble form. 
Periplasmic insoluble material is typically not accessed and therefore ignored in the 
productivity figures.  
Figure 10 shows expression levels of 24 recombinant proteins, mostly biopharmaceuticals 
that are expressed in Escherichia coli platforms. Induction is platform-dependent either by 
the addition of a corresponding sugar or by entering the stationary phase.  
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Fig. 10. Expression titres obtained for 24 different recombinant proteins mostly 
biopharmaceuticals. The proteins were expressed in either one of the sugar inducible or one of 
the stationary phase inducible Escherichia coli systems belonging to Lonza XS TechnologiesTM 
platform. Among the 24 recombinant products were fragment antibodies, Fab-fusions, single-
chain antibodies, virus-like particles, novel non-antibody type binders, growth factors, 
recombinant enzymes, amphipathic proteins, recombinant vaccines, peptides (hormones and 
others), affinity ligands and monomers of biopolymers; size of the proteins varied between 2 
and 220 kDa. Legend: C1, insoluble as inclusion bodies in cytoplasm; C2, soluble in cytoplasm; 
C3, soluble in cell-free medium; C4, soluble in periplasm. 
Cytoplasmic expression (categories C1 and C2). Among the products expressed in the 
cytoplasm, either soluble or insoluble as inclusion bodies, were highly soluble 
recombinant proteins as well as proteins prone to high aggregation propensity belonging 
to product classes such as recombinant vaccines, novel non-antibody based binders, 
recombinant therapeutic and non-therapeutic enzymes, virus like particles (VLPs), 
peptides (hormones and others), monomers of biopolymers, affinity ligands and others. 
The proteins were mostly monomeric with the size ranging from 2 to 40 kDa. Highest 
expression titres are obtained in the case of cytoplasmic soluble expression (C2 in Figure 
10) with a median titre of 11 g/l culture broth and a range of 3 – 20 g/l. Intentional 
intracellular expression of recombinant protein in an insoluble state as inclusion bodies 
(C1 in Figure 10) resulted in a median titre of about 9 g/l, with a range of 3 - 15 g/l 
dependent on the target protein. 
Extracellular expression, periplasmic and into cell free medium (categories C3 and C4). 
Products that were expressed with a signal sequence were fragment antibodies (Fab), Fab 
fusion proteins, single chain antibodies (scFv), growth factors, enzymes and various formats 
of amphipathic proteins. The size of the corresponding products varied between 20 and 220 
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kDa. Among them were both soluble and fairly soluble monomers and multimers, homo- 
and heteromers. Extracellular product (C3 in Figure 10) reached concentrations in the range 
of 0.5 to 8.5 g/l in the cell free medium with a median of 1.5 g/l. Proteins which 
accumulated in the periplasm (C4 in Figure 10) reached titres of functional product between 
0.5 and 10 g/l with a median titre of 2.0 g/l. Dependent on the product-specific aggregation 
propensity sometimes significant amounts of precipitated recombinant protein were 
observed in the periplasm. This fraction has been ignored, since it does not contribute to 
functional product. The extent of product precipitation can be influenced by the choice of 
the promoter system, the related induction mode and fermentation conditions. Similarly, the 
distribution of product between the periplasm and the cell-free medium can be partly 
controlled by changes in physical and chemical environmental conditions. However, ideal 
conditions need to be identified empirically. 
The above mentioned product titres have been typically obtained within 36 to 72 hours of 
fermentation.  
4.5 Posttranslational modification in Escherichia coli 
Proteins often require posttranslational modification in order to gain full biological activity. 
Therefore, missing posttranslational protein modification capabilities such as glycosylation, 
formation of pyroglutamic acid at the N-terminus, N-terminal acylation and C-terminal 
amidation are frequently cited as a disadvantage of bacterial expression.  
However, over the last decade big advances have been made in understanding glycosylation 
mechanisms and in glycoengineering of microbial organisms. Gerngross and coworkers 
(Choi et al., 2003) and Contreras and coworkers (Vervecken et al., 2004) were among the first 
to succeed in glycoengineering yeast more precisely, Pichia pastoris, towards the formation of 
defined glycoforms. The yeast related work culminated in successful expression of human-
like glycosylated antibody in a Pichia pastoris host, that enables specific human N-
glycosylation with high fidelity (Potgieter et al., 2009).  
In parallel it became evident that protein glycosylation is also abundant in prokaryotes. 
Whereas N-linked protein glycosylation is the most abundant posttranslational 
modification in eukaryotes, within prokaryotes it seems to be restricted to the domain of 
the Archea where S-layer proteins show N-linked glycosylation. Already in 2002 Aebi and 
coworkers (Wacker et al., 2002) demonstrated successful transfer of the Campylobacter 
jejuni protein N-glycosylation machinery into Escherichia coli. This opened up an exciting 
opportunity to produce N-glycoproteins within bacterial expression platforms. 
Nevertheless, two features were inhibitory to a broad application of the new system. (a) 
The Campylobacter jejuni glycan is immunogenic for humans. (b) The glycan is linked to 
asparagine through an unusual deoxysugar, bacillosamin. Recently the system has been 
further developed towards formation of the required N-acetylglucosamin-asparagine 
linkage that is commonly found in glycoproteins of eukaryotic origine (Schwarz et al., 
2010). The same paper proposes a semi-synthetic approach towards human glycosylation 
based on the new developed technology. 
The goal of any microbial glycoengineered system must be to overcome the weaknesses of 
the existing mammalian platforms that are, (a) mammalian glycosylation is characterized by 
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naturally occurring heterogeneity in the glycan structure and (b) by limited possibilities to 
tailor glycosylation towards improved therapeutic performance. Consequently microbial 
glycoengineered expression platforms should allow for tailored, homogenous and human-
like glycosylation. However the challenges on the way to the development of a well 
performing microbial glycoengineered platform are manifold. The following lists the 
technical obstacles that need to be addressed:  
1. glyoform homogeneity, ideally one glycoform should be formed 
2. tailoring, access to a number of specific glycoforms through defined host backgrounds 
3. productivity, volumetric productivity should not be below the productivity of existing 
mammalian systems 
4. O-glycosylation, existing yeast O-glycosylation causes immunogenic reactions with 
humans 
5. glycosylation efficiency, the whole of the target protein is expected to be glycosylated 
6. secretion efficiency, needs to be high, since glycosylation is connected to secretion 
7. expression of complex proteins such as antibodies, capability to produce hetero-
multimers (disulphide bridges) 
8. plug and play, access to stable glycoengineered hosts, such that only the target gene 
needs to be inserted 
9. proteases, deletion of all undesirable proteolytic activity 
10. good growth characteristics, system viability is affected by the amount of genetic 
changes 
11. N-terminal variability, often seen in yeast systems, needs to be under control 
As mentioned before, existing mammalian expression technology is not fulfilling all of the 
desirable requirements and there is an even longer way to go for the existing yeast 
systems in order to compete with mammalian systems. Not all of the above mentioned 
technical challenges have been successfully addressed in yeast. Even further away from 
technical maturity are bacterial glycoengineered systems. Nevertheless technical advances 
are achieved at high pace. The authors would not be surprised if bacterial expression 
technology would one day be a viable solution for large scale manufacturing of 
glycoproteins. 
4.6 Cost considerations 
From a commercial point of view, bacterial and yeast systems share many advantages over 
mammalian systems such as high growth rate, the potential to reach high biomass 
concentration, structural and segregational robustness and a higher product production rate 
rP, resulting in significantly shorter fermentation times. While mammalian cells such as 
CHO cells are characterized by a high specific product production rate qP, volumetric 
productivity QP is typically negatively affected by a relatively low growth rate and more 
importantly by the lower achievable biomass concentration as compared to Pichia pastoris 
(Kunert et al., 2008). The same is true, when comparing CHO cells to Escherichia coli. Other 
aspects such as time required for the development of a stable CHO cell line and media costs 
should be considered as well. All these aspects add to the attractiveness of microbial and 
yeast systems when the manufacture of aglycosylated non-antibody type of recombinant 
proteins is considered. Table 10 shows cost drivers in fermentation of the current key 
biopharmaceuticals production platforms. 
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Characteristics driving USP cost Bacteria Yeast Mammalian Cells 
 
Growth rate  [ 1/h] 
Final dry biomass concentration [g/l] 
Typical duration of fermentation [days] 
Specific product production rate qP [g/gh] 1)
Volumetric productivity QP [g/lh] 1) 
 
Medium cost 
Strain development cost and duration 
Equipment standard 
 
 
0.7 
60-70 
2-3 
0.002 
0.10 
 
low 
low 
steel 
 
0.2 
80-100 
4-5 
0.001 
0.05 
 
low 
medium 
steel 
 
0.02 
3-8 
15-20 
0.005 
0.01 
 
high 
high 
steel, disposable 
Table 10. Comparison of bacterial, yeast and mammalian system characteristics which drive 
cost of goods in fermentation; 1) the figures have been modelled based on typical production 
key figures and assuming an equal product titre of 5 g/l at the end of the fermentation; USP, 
upstream processing. 
Methylotrophic yeast fermentation can be very demanding on equipment performance as a 
result of the high oxygen demand, high cooling requirements and explosion-proof design 
because of methanol feeding. Corresponding bioreactor layout requirements are described 
by Hoeks et al. (2005).  
Figure 7 shows that about 9% of all recombinant DNA products are supposedly 
manufactured with transgenic animals, avian cells, insect cells and viral platforms. On top of 
these, there are early projects of recombinant expression in plants, filamentous fungi, plants 
and protozoa. The decision to opt for one of these systems is mostly driven by specific 
product aspects, cost or IP reasons in order to gain freedom to operate. A cost advantage 
through higher productivity or lower depreciation compared to more conventional systems 
is not obvious. Cost allocated to fermentation is typically in the range of 30% to 50% of 
overall manufacturing costs. Irrespective of the recombinant biosynthesis method used, the 
DSP costs remain. Therefore the sometimes cited 10X overall cost improvement through the 
use of one specific expression system and the related USP production platform is difficult to 
understand if not unrealistic.  
The cost of downstream processing (DSP) is more or less independent of the chosen system, 
if we assume product localization in the cell-free medium. When using Gram-negative 
expression technology special attention needs to be paid to endotoxin removal. On the other 
hand a mammalian system makes viral clearance mandatory.  
Intracellular production obviously requires cell disruption or product release from the cells 
followed by a usually more complex biomass removal step. The latter is more or less 
standardized for conventional expression technologies. Other operations such as inclusion 
body isolation and purification followed by protein refolding typically drive DSP costs up. 
Theses higher costs for DSP can only be justified through higher upstream productivity as 
shown in Figure 10 or a lack of production alternatives. It is also obvious that no significant 
cost advantage is to be expected on the DSP side, if product needs to be extracted and 
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purified out of whole plants. However, in the latter case a significant cost advantage arises if 
for example, a therapeutic or a vaccine is administered through oral consumption of the 
whole plant or a non-purified low-cost plant extract.  
Please note that other costs for so called secondary manufacturing (e.g fill and finish, 
formulation) accrue for the finished product, which we can not discuss here.  
5. Conclusions 
The industry has become very conservative, risk averse and reluctant to change established 
and successful manufacturing platforms because of a very strict interpretation of regulatory 
guidelines. This is also the main reason why the authors think that the main load of 
biotechnological manufacturing production has remained with the already industrially 
established microbial (E. coli, yeast) and mammalian production systems and will continue 
to do so. Nevertheless, regulatory government bodies do welcome novel manufacturing 
methods for the production of affordable pharmaceuticals because of ever increasing health 
care costs. Indeed, it cannot be denied that cost pressure and novel applications will help to 
disturb the established situation. We consider two alternative expression systems to have 
some potential. 
1. Transgenic plants have the possibility to combine therapeutic with nutrition needs. The 
production of edible vaccines for human or veterinary applications for example appear 
to be an attractive option especially as the active crop can be phototrophically and 
cheaply grown locally. 
2. Due to their short doubling times and easier cultivation, protozoa offer themselves as a 
possibility between microbial and mammalian cell culture. Insect cell culture seem to be 
not as attractive as protozoa as they do not grow as fast and the frequently used BEVS 
results in more complex isolation and purification procedures. 
These two options, however, will again be hampered by another expected or even partly 
realised breakthrough: the successful targeted humanised glycosylation in yeast and later in 
bacteria. On top of that, we will sooner or later experience the realisation of extensive 
pathway engineering and synthetic biology principles, where production organisms will be 
designed using engineering principles as in the automotive or aerospace industry. It is even 
harder to imagine how and where alternatives such as plants or protozoa can beat such 
advanced microbial or mammalian options.  
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